Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded at a new 52-week low today of $4.60. This new low was reached on above average trading volume as 478,000 shares traded hands, while the average 30-day volume is approximately 238,000 shares.
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) has potential upside of 29.9% based on a current price of $4.72 and analysts’ consensus price target of $6.13.
In the past 52 weeks, shares of Freeline Therapeutics Holdings plc have traded between the current low of $4.60 and a high of $21.69 and is now at $4.72.
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, and FLT190 for the treatment of Fabry disease.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer